pipobroman (vercyte) Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death   NCATS

Chemistry

  • SMILES: BrCCC(=O)N1CCN(CC1)C(=O)CCBr
  • InChIKey: NJBFOOCLYDNZJN-UHFFFAOYSA-N
  • Mol. Mass: 356.054
  • ALogP: 1.23
  • ChEMBL Molecules:
    pipobroman  
    calcium glubionate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

a-8103 | amedel | pipobroman | vercyte

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Leukemia, Myeloid, Chronic-Phase (approved 1966)

Polycythemia Vera (approved 1966)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue